Nothing Special   »   [go: up one dir, main page]

ZA941464B - Use of pregnane derivative - Google Patents

Use of pregnane derivative

Info

Publication number
ZA941464B
ZA941464B ZA941464A ZA941464A ZA941464B ZA 941464 B ZA941464 B ZA 941464B ZA 941464 A ZA941464 A ZA 941464A ZA 941464 A ZA941464 A ZA 941464A ZA 941464 B ZA941464 B ZA 941464B
Authority
ZA
South Africa
Prior art keywords
pregnane
pregnane derivative
alpha
derivative
oacyl
Prior art date
Application number
ZA941464A
Other languages
English (en)
Inventor
Godefridus Hermanus Jo Deckers
Helenius Jan Kloosterboer
Original Assignee
Akzo Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nv filed Critical Akzo Nv
Publication of ZA941464B publication Critical patent/ZA941464B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Fats And Perfumes (AREA)
ZA941464A 1993-03-05 1994-03-02 Use of pregnane derivative ZA941464B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP93200631 1993-03-05

Publications (1)

Publication Number Publication Date
ZA941464B true ZA941464B (en) 1994-09-27

Family

ID=8213673

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA941464A ZA941464B (en) 1993-03-05 1994-03-02 Use of pregnane derivative

Country Status (14)

Country Link
US (1) US5512556A (ja)
EP (1) EP0613687B1 (ja)
JP (1) JP3391539B2 (ja)
KR (1) KR100312061B1 (ja)
AT (1) ATE180669T1 (ja)
AU (1) AU671706B2 (ja)
CA (1) CA2116829C (ja)
DE (1) DE69418744T2 (ja)
DK (1) DK0613687T3 (ja)
ES (1) ES2134313T3 (ja)
GR (1) GR3031114T3 (ja)
NO (1) NO307447B1 (ja)
NZ (1) NZ260017A (ja)
ZA (1) ZA941464B (ja)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996009056A1 (en) * 1994-09-22 1996-03-28 Akzo Nobel N.V. Process of making dosage units by wet granulation
IL123984A (en) * 1997-04-22 2004-09-27 Akzo Nobel Nv Pharmacological dosage units containing tibolone and carrier pharmacy are acceptable
NZ510501A (en) * 1998-10-16 2003-10-31 Akzo Nobel Nv High purity composition comprising (7alpha,17beta)- 17- hydroxy- 7-methyl- 19-nor-17-pregn- 5(10)-en-20-yn-3-one
AU5209600A (en) * 1999-04-06 2000-10-23 Akzo Nobel N.V. Orally active androgens
CN100354299C (zh) * 1999-09-06 2007-12-12 欧加农股份有限公司 在11位带有烃取代基的非芳香族雌激素甾族化合物
KR20030029640A (ko) 2000-07-28 2003-04-14 악조 노벨 엔.브이. 16 알파-메틸 또는 에틸 치환 에스트로겐
GB0125061D0 (en) * 2001-10-18 2001-12-12 Norton Healthcare Ltd Pharmaceutical composition
ES2284946T3 (es) * 2001-10-18 2007-11-16 Norton Healthcare Limited Formulaciones de tibolona.
EP1469861A1 (en) * 2002-01-22 2004-10-27 Akzo Nobel N.V. Tibolone in the treatment of complaints associated with the administration of drugs which prevent the synthesis of endogenous estrogen
US20060051420A1 (en) * 2002-11-20 2006-03-09 Pieter De Haan Pharmaceutical tablets containing tibolone and a coating
UA89964C2 (ru) 2004-09-08 2010-03-25 Н.В. Органон 15β-ЗАМЕЩЕННЫЕ СТЕРОИДЫ, КОТОРЫЕ ИМЕЮТ СЕЛЕКТИВНУЮ ЭСТРОГЕННУЮ АКТИВНОСТЬ
US20060211667A1 (en) * 2005-03-21 2006-09-21 Eric Marchewitz Use of pregnane steroid derivatives for enhancing physical performance
CN116987680A (zh) * 2022-04-25 2023-11-03 复旦大学 支链氨基酸转氨酶1的功能获得性突变体及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4701450A (en) * 1984-03-21 1987-10-20 Akzo N.V. Steroids for use as immunomodulators
IE63051B1 (en) * 1989-03-18 1995-03-22 Akzo Nv Pharmaceutical composition which contains a pharmaceutically suitable carrier and the compound having the structure (7alpha, 17alpha)-17-Hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn- 3-one
FR2706454B1 (fr) * 1993-06-17 1995-09-15 Roussel Uclaf Nouveaux 19-Nor stéroïdes, procédé et intermédiaires de préparation, application comme médicaments et compositions pharmaceutiques les contenant.

Also Published As

Publication number Publication date
DE69418744T2 (de) 1999-11-11
AU5754294A (en) 1994-09-08
EP0613687B1 (en) 1999-06-02
DK0613687T3 (da) 1999-12-06
JP3391539B2 (ja) 2003-03-31
KR940021064A (ko) 1994-10-17
DE69418744D1 (de) 1999-07-08
NO307447B1 (no) 2000-04-10
US5512556A (en) 1996-04-30
CA2116829C (en) 2004-09-14
GR3031114T3 (en) 1999-12-31
JPH072673A (ja) 1995-01-06
NO940777L (no) 1994-09-06
KR100312061B1 (ko) 2001-12-28
ES2134313T3 (es) 1999-10-01
EP0613687A1 (en) 1994-09-07
AU671706B2 (en) 1996-09-05
ATE180669T1 (de) 1999-06-15
NO940777D0 (no) 1994-03-04
NZ260017A (en) 1997-06-24
CA2116829A1 (en) 1994-09-06

Similar Documents

Publication Publication Date Title
IL136044A (en) 2-aminoacetamide derivatives and pharmaceutical compositions containing the same
RU2088589C1 (en) Derivatives of 17 beta-substituted-4-aza-5-5 alpha-androstane-3-ones, methods of synthesis of compounds, pharmaceutical composition, compound 4
IL175398A0 (en) Steroidal compounds and pharmaceutical compositions containing them for treating oxidative stress and inflammation
IL128568A0 (en) Use of cyclooxygenase-2 inhibitors for the manufacture of a medicament for the treatment and prevention of neoplasia
IL113581A0 (en) Propiophenone derivatives their preparation and pharmaceutical compositions containing them and their use
MY113733A (en) Salts of an anti-migraine indole derivative
EP0807633A3 (en) Novel 2,3-disubstituted-(5,6)- heteroarylfused-pyrimidine-4-ones
AU2246292A (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
ZA941464B (en) Use of pregnane derivative
MD1560F2 (en) Cyclic compounds, pharmaceutical compositions on base thereof and methods of treatment of infections or diseases provoked by retroviruses.
TW223016B (ja)
MY114282A (en) Anthracycline derivatives
GB9302046D0 (en) Antiumoral compound-v
HU9400908D0 (en) Pharmaceutical compositions for treatng skin disorders
TW330933B (en) Furanoeremophilane and eremophilanolide sesquiterpenes for treatment of diabetes
IL131380A0 (en) The use of a compound for the manufacture of a pharmaceutical preparatin for the treatment or prevention of prostate cancer
PL318539A1 (en) Inhibition of biosynthesis
AP9400608A0 (en) "New nicotinic acid derivative".
HK1007857A1 (en) New compound leustroducsin H its preparation and its therapeutic use
GR3036968T3 (en) Adamantyl substituted oxindoles as pharmaceutical agents